Witnessing the stock’s movement on the chart, on Wednesday, Cullinan Therapeutics Inc (NASDAQ: CGEM) had a quiet start as it plunged -3.97% to $12.58, before settling in for the price of $13.10 at the close. Taking a more long-term approach, CGEM posted a 52-week range of $7.64-$30.19.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded -20.00%. Meanwhile, its Annual Earning per share during the time was -62.42%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 17.78%. This publicly-traded company’s shares outstanding now amounts to $42.90 million, simultaneously with a float of $37.06 million. The organization now has a market capitalization sitting at $732.50 million. At the time of writing, stock’s 50-day Moving Average stood at $16.24, while the 200-day Moving Average is $18.44.
Cullinan Therapeutics Inc (CGEM) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Cullinan Therapeutics Inc’s current insider ownership accounts for 36.36%, in contrast to 77.28% institutional ownership. According to the most recent insider trade that took place on Nov 05 ’24, this organization’s Chief Scientific Officer sold 8,000 shares at the rate of 15.64, making the entire transaction reach 125,120 in total value, affecting insider ownership by 107,942. Preceding that transaction, on Sep 05 ’24, Company’s Chief Scientific Officer sold 8,000 for 18.09, making the whole transaction’s value amount to 144,720. This particular insider is now the holder of 115,942 in total.
Cullinan Therapeutics Inc (CGEM) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.84 per share during the current fiscal year.
Cullinan Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 17.78% and is forecasted to reach -3.12 in the upcoming year.
Cullinan Therapeutics Inc (NASDAQ: CGEM) Trading Performance Indicators
Let’s observe the current performance indicators for Cullinan Therapeutics Inc (CGEM). It’s Quick Ratio in the last reported quarter now stands at 24.46. The Stock has managed to achieve an average true range (ATR) of 1.02.
In the same vein, CGEM’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.88, a figure that is expected to reach -0.79 in the next quarter, and analysts are predicting that it will be -3.12 at the market close of one year from today.
Technical Analysis of Cullinan Therapeutics Inc (CGEM)
Going through the that latest performance of [Cullinan Therapeutics Inc, CGEM]. Its last 5-days volume of 0.63 million was inferior to the volume of 0.65 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 3.50% While, its Average True Range was 1.05.
Raw Stochastic average of Cullinan Therapeutics Inc (CGEM) in the period of the previous 100 days is set at 0.94%, which indicates a major fall in contrast to 1.60% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 69.67% that was higher than 58.96% volatility it exhibited in the past 100-days period.
